* CASI Pharmaceuticals Inc CASI.OQ reported a quarterly
adjusted
loss of 4 cents per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 6 cents per share.
* Revenue rose 89.9% to $9.16 million from a year ago;
analysts
expected $9.07 million.
* CASI Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 4 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* CASI Pharmaceuticals Inc shares had risen by 13.8% this
quarter.
* The company reported a quarterly loss of $5.6 million.
* Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $4.00
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated March 29 at 07:09 p.m. All
figures in US dollars unless otherwise stated